Latest news with #precision medicine
Economy ME
5 days ago
- Health
- Economy ME
MBRU scientists publish first Arab Pangenome Reference in major genomic breakthrough
Scientists at the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), the academic and research arm of Dubai Health , have achieved a major milestone in global genomic science with the publication of the first Arab Pangenome Reference. Featured in Nature Communications , a leading peer-reviewed journal, the study marks a pivotal advancement in precision medicine and personalized healthcare for Arab populations. The landmark achievement supports the UAE's National Genome Strategy, a 10-year initiative launched in 2023 by the Emirates Genome Council. The strategy aims to transform healthcare in the UAE through cutting-edge genomic research focused on personalized, preventive, and precision medicine. The Arab Pangenome Reference was created using high-quality DNA sequencing from 53 individuals of diverse Arab heritage residing in the UAE. Conducted at MBRU's state-of-the-art Center for Applied and Translational Genomics (CATG), the research identified more than 110 million base pairs of novel DNA sequences. Additionally, it uncovered nearly 9 million small genetic variations and over 235,000 large structural differences unique to Arab populations — none of which had been previously reported in global DNA references. Read: Sheikh Hamdan awards golden visas to nurses with 15+ years of service at Dubai Health Leadership insights Professor Alawi Alsheikh-Ali , director general, Dubai Health Authority (DHA), and co-author of the study, said: 'This achievement strengthens the UAE's position in genomic science. By building a reference that reflects the genetic diversity of Arab populations, we are enabling more precise and equitable healthcare. It's a foundational step towards realising the goals of our National Genome Strategy and ensuring that future medical innovations are shaped by data from our own communities.' Dr. Hanan Al Suwaidi, acting Provost of MBRU, and co-author of the study said: 'The capabilities of the CATG lab were central to the success of this project. From genetic sequencing to advanced bioinformatics, every stage of the research was completed in-house. This level of integration gave us full control over quality and timelines, reflecting Dubai Health's commitment to building world-class infrastructure and fostering national scientific leaders.' Dr. Mohammed Uddin, director of CATG and associate professor of Genetics at MBRU, and senior author of the study, said: 'This pangenome reference marks a major advancement in our understanding of Arab genomic diversity. It serves as a critical resource for both research discovery and clinical genome diagnostics, with lasting impact for future generations across the region.' Professor Alawi Alsheikh-Ali, director general, Dubai Health Authority (DHA) Addressing gaps in global genomic databases Historically, global genomic databases have significantly underrepresented Arab populations, limiting the accuracy of genetic risk assessment and treatment strategies for these communities. The Arab Pangenome Reference fills a critical gap by introducing high-resolution genomic data from a population long absent in international references. One particularly notable finding from the study was the discovery of the duplicated gene TAF11L5, which is highly enriched among Arab individuals but missing in existing global genomic references. Researchers believe this gene could influence the regulation of other genes and may hold important insights into disease risk and variations in treatment response. Enabling precision healthcare in the Arab World The Arab Pangenome Reference provides a foundational tool for national and regional precision medicine initiatives. It enables the development of population-specific biomarkers, disease risk models, and targeted therapies — advancing the region's ability to deliver more accurate, personalized healthcare solutions. Alongside the genomic map, the research team also introduced a new bioinformatics tool called PanScan. Designed to support more complex analysis of human pangenomes, PanScan helps researchers detect gene duplications, novel DNA variants, and complex genomic structures. Though not the main focus of the study, the tool has been made freely available on GitHub, offering global researchers access to further investigate human genomic diversity. The strategy aims to transform healthcare in the UAE through cutting-edge genomic research focused on personalized, preventive, and precision medicine A strategic step toward global representation Genomic research has progressed rapidly in recent decades, but much of the foundational data has come from a limited range of populations, creating blind spots in medical understanding. The Arab Pangenome Reference contributes to a growing international effort to correct this imbalance and promote global inclusivity in genomic science. The initiative also reflects Dubai Health's long-term commitment to research and innovation through MBRU. By investing in foundational studies such as this, Dubai Health is ensuring that Arab populations are actively represented in the future of genomics and precision healthcare. This groundbreaking research not only elevates the UAE's position in global genomic science but also lays the groundwork for more equitable, effective, and personalized healthcare systems across the Arab World.
Yahoo
6 days ago
- Business
- Yahoo
Next-Generation Sequencing Enhancing Accuracy, Precision Medicine Advancements Propel Growth
The global companion diagnostics market is set to surge from USD 7.03 Billion in 2024 to USD 22.83 Billion by 2034, driven by rising cancer prevalence and precision medicine advancements. Key trends include enhanced diagnostic technologies like NGS and PCR, regulatory approvals, and growing targeted therapies demand. Companion Diagnostics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Companion Diagnostics Market Report and Forecast 2025-2034" report has been added to global companion diagnostics market was valued at USD 7.03 Billion in 2024, driven by the rising prevalence of cancer across the globe. The market is anticipated to grow at a CAGR of 12.50% during the forecast period of 2025-2034 to achieve a value of USD 22.83 Billion by 2034. Companion diagnostic tests help in the diagnosis of diseases and determines the most effective drug for a specific patient. These tests are crucial in cancer treatment, identifying biomarkers that indicate a patient's suitability for individualised treatment. Pharmaceutical companies integrate companion diagnostics into drug development to enhance efficacy, ensuring that only patients most likely to benefit receive targeted global companion diagnostics market is witnessing robust growth due to advancements in precision medicine and increasing demand for targeted therapies. Rising cancer prevalence, the need for biomarker-based diagnostics, and regulatory support for new test approvals drive market expansion. Moreover, the growing adoption of next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies further enhances diagnostic accuracy, enabling personalised treatment Drivers and Adoption TrendsThe companion diagnostic market is expanding due to rising demand for precision cancer treatments. Companies like Foundation Medicine lead innovations with products like FOUNDATIONONE CDx, which analyses cancer-related genes in solid tumors. Increasing regulatory approvals and advancements in companion diagnostic tests further support market growth. The rising prevalence of cancer has prompted greater adoption of companion diagnostics, ensuring effective treatment Approvals and COVID-19 ImpactThe U.S. FDA is approving novel companion diagnostic (CDx) tests, such as the Oncomine Dx Target Test by Thermo Fisher Scientific Inc., designed to detect HER2 (ERBB2) activating mutations in non-small cell lung cancer. However, the COVID-19 pandemic initially reduced demand for companion diagnostics products, delaying novel diagnostic tests. Despite this, the global companion diagnostics market is expected to recover and expand significantly during the forecast Companion Diagnostics Market TrendsExpanding IndicationsThe market is broadening beyond oncology to include neurological, cardiovascular, and infectious diseases. Regulatory approvals for new indications enable the development of biomarker-driven therapies, improving patient outcomes. This trend enhances diagnostic applications, supporting pharmaceutical innovations and expanding the market's potential across diverse therapeutic on Precision MedicineThe shift towards precision medicine is driving the demand for companion diagnostics, ensuring targeted drug selection. Advances in genomic profiling allow for personalised treatment plans, reducing adverse reactions and enhancing efficacy. Pharmaceutical companies increasingly integrate biomarker-based diagnostics to develop tailored therapies, improving patient care and optimising treatment Healthcare ExpendituresIncreasing healthcare investments globally support the growth of companion diagnostics, with governments and private entities funding research and development. The demand for early disease detection and advanced diagnostics drives higher spending, ensuring improved diagnostic capabilities and expanding access to innovative treatments, particularly in emerging in TechnologiesCutting-edge technologies like next-generation sequencing (NGS), artificial intelligence (AI), and digital pathology enhance the efficiency of companion diagnostics. Automated platforms enable faster, more accurate biomarker detection, supporting precision medicine. Continuous innovation in diagnostic tools strengthens the market, improving patient outcomes through highly specialised, data-driven Diagnostics Market Growth Factors Rising Cancer Incidence to Drive the Demand for Companion DiagnosticsThe increasing global burden of cancer is a key factor propelling the growth of the companion diagnostics market. According to the American Cancer Society, cancer cases are projected to reach 35 million by 2050, primarily due to population growth and ageing demographics. This surge in cases necessitates advanced diagnostic solutions for early detection, effective treatment, and improved patient outcomes. Companion diagnostics play a crucial role in guiding targeted therapies, ensuring personalised treatment strategies, and enhancing the efficacy of cancer technological advancements such as next-generation sequencing (NGS) and liquid biopsy techniques have further bolstered market expansion. These innovations facilitate rapid genetic profiling, helping oncologists identify specific biomarkers associated with different cancer types. The rising adoption of precision medicine by healthcare providers and pharmaceutical companies is also a significant growth driver. As demand for customised cancer treatments increases, the market for companion diagnostics is expected to expand Approvals for Novel Diagnostic Tests to Fuel Market ExpansionThe approval of new companion diagnostic tests for various indications is another critical factor driving market growth. Regulatory bodies such as the U.S. FDA, European Medicines Agency (EMA), and other global health authorities continue to approve innovative diagnostic solutions for targeted therapies. These approvals validate the clinical efficacy of companion diagnostics, increasing their adoption across healthcare facilities. The expanding pipeline of biomarker-driven therapies further encourages diagnostic companies to develop novel tests, contributing to overall market regulatory support ensures that new diagnostics meet stringent safety and accuracy standards, enhancing physician confidence in their effectiveness. Recent approvals of companion diagnostic assays for lung, breast, and colorectal cancers have provided patients with access to personalised treatment options. As pharmaceutical firms continue to collaborate with diagnostic developers, the market is poised for sustained growth, driven by innovation and regulatory Factors Challenges in Reimbursement Policies and Strict Regulatory Requirements Hindering Market GrowthThe companion diagnostics market faces significant challenges due to complex reimbursement policies. Many healthcare systems lack well-defined reimbursement frameworks for companion diagnostic tests, making it difficult for patients and healthcare providers to afford these tests. The high cost of developing and validating these diagnostics further complicates accessibility, limiting their widespread adoption. Additionally, variations in reimbursement policies across different countries create inconsistencies in market regulatory requirements act as another major barrier, as companion diagnostics must undergo rigorous approval processes to ensure accuracy and efficacy. Regulatory bodies such as the U.S. FDA, EMA, and other global agencies enforce strict guidelines, leading to prolonged approval timelines. Compliance with these complex regulations requires substantial investment and expertise, delaying market entry for new high cost of companion diagnostics is another critical factor restricting market expansion. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies involve expensive equipment and specialised expertise, making these diagnostics unaffordable for many healthcare institutions. The financial burden on smaller laboratories and emerging markets further limits accessibility, restricting the overall growth of the limited awareness and adoption rates in developing regions pose additional challenges. A lack of trained professionals, inadequate infrastructure, and limited integration of precision medicine hinder the widespread implementation of companion diagnostics. Addressing these barriers requires increased investment in education, regulatory simplifications, and improved reimbursement models to unlock the market's full potential. Key Industry Developments In October 2024, Roche secured FDA approval for its VENTANA Claudin 18 (43-14A) RxDx Assay, making it the first immunohistochemistry (IHC) companion diagnostic for CLDN18 protein expression in gastric and gastroesophageal junction adenocarcinoma patients. This breakthrough enabled eligible patients to receive Astellas' targeted therapy VYLOY (zolbetuximab), enhancing treatment precision in gastrointestinal cancers. In August 2024, Illumina, Inc. announced FDA approval of its TruSightT Oncology (TSO) Comprehensive test, a single in vitro diagnostic (IVD) that can profile over 500 genes in solid tumors. This test is designed to identify both adult and pediatric patients with solid tumors that have neurotrophic tyrosine receptor kinase (NTRK) gene fusions. If the test detects this, the patient may benefit from Bayer's VITRAKVI (larotrectinib). The test is also approved for identifying adult patients with advanced or metastatic non-small-cell lung cancer (NSCLC) that has rearranged during transfection (RET) gene fusions. These patients may benefit from treatment with Lilly's RETEVMO (selpercatinib). In August 2024, QIAGEN expanded its collaboration with AstraZeneca to develop companion diagnostics (CDx) for chronic diseases. Using QIAGEN's QIAstat-Dx platform, the partnership aimed at create a genotyping assay that facilitates real-time patient screening, helping healthcare providers determine patient eligibility for AstraZeneca's genomically targeted medicines, ultimately improving treatment accessibility and clinical decision-making. In July 2024, BD and Quest Diagnostics entered a global collaboration to develop flow cytometry-based companion diagnostics (CDx) for cancer and other diseases. This partnership aimed at providing an end-to-end CDx solution pharmaceutical companies. It ranged from exploratory panel development to FDA-approved diagnostic kit distribution, so as to advance precision medicine for better treatment selection. Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $7.03 Billion Forecasted Market Value (USD) by 2034 $22.83 Billion Compound Annual Growth Rate 12.5% Regions Covered Global Supplier Landscape Abbott F. Hoffmann-La Roche Ltd. Agilent Technologies, Inc. Illumina, Inc. Guardant Health Thermo Fisher Scientific Inc. BIOMERIEUX QIAGEN Myriad Genetics, Inc. Global Companion Diagnostics Market SegmentationMarket Breakup by Offerings Products Assays, Kits and Reagents Instruments & Systems Software Services Market Breakup by Technology Polymerase Chain Reaction Immunohistochemistry In Situ Hybridization Next-Generation Sequencing Others Market Breakup by Indication Cancer Neurological Diseases Infectious Diseases Others Market Breakup by End User Pharmaceutical & Biopharmaceutical Companies Reference Laboratories Contract Research Organizations Others Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Companion Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Malay Mail
11-07-2025
- Health
- Malay Mail
Sabah's diverse DNA in spotlight as MyGenom project kicks off recruitment drive for precision medicine
KOTA KINABALU, July 11 — Recruitment for the MyGenom project has started in Sabah, with Deputy Health Minister Datuk Lukanisman Awang Sauni and Deputy Science, Technology and Innovation Minister Datuk Mohammad Yusof Apdal launching the Sabah Zone MyGenom Research Data Collection here today. The Ministry of Health (MOH) and the Ministry of Science, Technology and Innovation (MOSTI), in a joint statement, said that the initiative, which began in Kota Kinabalu, is being implemented through collaboration between MOH healthcare facilities and public higher education institutions (IPTA). They said that the collaborative move strengthens grassroots involvement and launches recruitment operations in urban and rural areas in Sabah, where the state, with its unique genetic and ethnic diversity, is given priority in this project. In this regard, the ministries urged Sabahans, particularly the Bumiputera community, who have been underrepresented in genomic research, to actively participate in the project, enabling them to benefit from advancements in precision medicine and future health policies. 'The MyGenom project is being carried out as a strategic effort to build the nation's genomic assets to strengthen the health system, through data and technology, in line with the aspirations of the Health White Paper and the Malaysia Madani framework. 'This project is being implemented under the National Biotechnology Policy 2.0 (DBN 2.0), through the Perdana 4 programme, which focuses on the application of genomics technology and targeted therapies to improve public health,' they said. Sabah with its unique genetic and ethnic diversity, is given priority in the MyGenom project. — Picture by Julia Chan Under the initiative, MOH is responsible for genomic sampling and public health-related analysis, while MOSTI, through the Malaysia Genome and Vaccine Institute (MGVI) under the National Institutes of Biotechnology Malaysia (NIBM), oversees the genome sequencing process using advanced facilities. The project is currently in Phase 1, with 3,150 participants recruited from Peninsular Malaysia and Sarawak since August 2024, nearing the total target of 3,600 participants. 'The National Institutes of Health (NIH) and the Institute for Medical Research (IMR) are leading this initiative, focusing on underrepresented communities, including the Bumiputera of Sabah and Sarawak, as well as the Orang Asli,' the ministries said. As of June 19, 2025, a total of 1,080 genomes have been successfully sequenced in Malaysia, with technical cooperation from MOH. This effort is supported by MOSTI's investment in a high-performance sequencing system, enabling more efficient processing of hundreds of samples while ensuring that the country's genetic data sovereignty is maintained. Phase 2 will be expanded, with a target of sequencing 10,000 genomes from Malaysians of diverse ethnicities, localities, and backgrounds, a crucial step to avoid bias in understanding diseases and treatment responses. 'This genomic data will be utilised in stages for the management of chronic diseases, such as heart disease, cancer, diabetes, and rare diseases,' they said. — Bernama
